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Teaser The association of reactive acyl-glucuronide drug metabolites with toxicity,
particularly hepatotoxicity, is a concern in drug discovery and development, which this
article puts into perspective in light of current knowledge.
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Acyl glucuronidation is a common metabolic fate for acidic drugs and
their metabolites and, because these metabolites are reactive, they have
been linked to adverse drug reactions (ADRs) and drug withdrawals.
However, alternative routes of metabolism leading to reactive metabolites
(e.g., oxidations and acyl-CoA thioesters) mean that unambiguous proof
that acyl glucuronides are toxic is lacking. Here, we review the synthesis
and reactivity of these metabolites, and describe the use of molecular
modelling and in vitro and in vivo reactivity assessment of acyl glucuronide
reactivity. Based on the emerging structure-dependent differences in
reactivity and protein adduction methods for risk assessm ent for acyl
glucuronide-forming acid drugs of drug candidates in drug discovery/
development are suggested.
Introduction
Glucuronidation is a common metabolic fate for a variety of drugs, and other xenob iotics and
their oxidative metabolites. In general, glucuronidation is considered to be a detoxication
reaction but, in the case of acidic drugs (or acidic metabolites of drugs produced via ester
hydrolysis or oxidative metabolism), the formation of acyl glucuronides is a likely metabolic
fate. Such an outcome is typical for, for example, nonsteroidal anti-inflammatory drugs (NSAIDs),
many of which are associated with liver or gut toxicity. As a result of the propensity for these drugs
to be metabolized to acyl glucuronides, and the long-recognized chemical reactivity of these
metabolites [1–5], an association between acyl glucuronide reactivity and toxicity has been made,
particularly for drug-induced liver injury (DILI). However, this association is a loose one and,
despite decades of research, absolute proof is still lacking. Thus, although there is clear evidence
for covalent binding to proteins for these metabolites, the situation is often complicated by the
fact that there is often concomitant metabolism via oxidative routes that form reactive metab-
olites that can also lead to covalent binding. A good case in point is diclofenac, which is associated
with a high level of ADRs, including DILI; there is also clear evidence from patients of circulating
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IEWdducts to human serum albumin (HSA) [6] in the absence of
bvious toxicity, although CYP P450-related reactive metabolism
 also significant [7]. Perhaps the best evidence for reactive acyl
lucuronides being the cause of DILI is the fact that those with the
stest transacylation rates in buffer tend to be associated with the
ost compound withdrawals and/or black box warnings [8] How-
ver, such high rates of rearrangement might simply be pointing
owards some other steric or electronic property of the molecule
hat makes it susceptible to other mechanisms of toxicity (i.e., the
rmation of reactive S-acyl CoA esters; e.g., [9–13]).
Whatever the case, the formation of ester glucuronides has
ttracted regulatory opprobrium and they are considered to be
oxic per se regardless of whether this is in fact the cause. Such
egulatory concerns were first highlighted in the US Food and Drug
dministration (FDA) regulatory Guidance on the Safety testing of
etabolites, which essentially labelled acyl glucuronides as toxic
4]. In addition, a recent industry and regulatory publication [15]
ontained statements such as ‘ . . . O-glucuronides, O-sulfates, and
uaternary N+-glucuronides may be considered benign from a
uman safety perspective, animal coverage of acyl glucuronides
ould still be warranted because of reactivity concerns’. In addition
o glucuronidation, the carboxylate function is subject to other
ypes of conjugation, including highly reactive S-acyl CoA con-
gates, and these have been accorded little regulatory attention
2]. Indeed, in one study, it was noted that acyl glucuronides with
 high acyl migration rate combined with a high daily dose, plus
he presence of S-acyl CoA conjugates (or further downstream acyl
oA-derived metabolites) correlated with ‘a higher probability to
ause drug-induced liver injury’ [10]. An alternative conclusion
ight be that it was the CoA metabolites that were the toxins and
he acyl glucuronides innocent bystanders, a view reinforced by a
ecent study on p-alkyl-benzoyl-CoA conjugates [13].
So, despite many years of research the situation is still, in our
iew (and indeed that of many others), unresolved. There remains
 lack of convincing evidence for the acyl glucuronides, as a class,
eing a cause of human DILI. Nevertheless, such opinions should
e a spur to action, and it is the case that the finding of an acyl
lucuronide as a metabolite of a carboxylic acid-containing drug
resents a problem for both drug discovery and development. The
ame applies to compounds such as celecoxib, which, although
ot a carboxylic acid itself, acquires such a group as a result of
xidative metabolism and that metabolite goes on to form an acyl
lucuronide [16].
The situation with respect to potential acyl glucuronide toxicity
is made worse by a lack of any form of predictive animal model
that can be used to test the hypothesis. In such a situation, the best
that can be done until predictive models are available, or acyl
glucuronides are removed from the toxin list, is to follow best
practice, and a good example of this was recently provided by
Smith et al. [3], who advanced a ‘simplified paradigm’ for the safety
assessment of acyl glucuronides that provides valuable guidance
for a pragmatic approach to dealing with this problematic class of
reactive metabolites. Here, we highlight the current state of the art
in certain areas of the field, make suggestions as to approaches to
testing the hypothesis that acyl glucuronides are indeed toxic, and
provide additional tools to aid decision making.
Synthetic aspects of acyl glucuronides
In their proposed simplified approaches to the safety assessment of
these metabolites Smith et al. [3] stated that ‘The instability of acyl
glucuronides in aqueous solution poses formidable challenges in
establishing appropriate tests for an unqualified acyl glucuronide .
. . .’ which is indeed the case. They went on to state that the
‘Isolation or chemical synthesis of acyl glucuronides is possible,
but extremely difficult in any quantity’ and, although agreeing with
the first part of this sentence, we would suggest that advances in
synthetic methods for these metabolites have advanced to the stage
where the chemical synthesis of these compounds in quantity is
feasible using accessible and published procedures based on the
selective acylation method. This versatile and efficient approach
to acyl glucuronide synthesis relies on the kinetic anomeric effect,
through which 1b-acylation is favoured over 1a- in a mildly basic
medium. Moreover, this method requires only monoprotection,
typically using either allyl [17] or benzyl [18] D-glucuronate. In this
way, the synthesis of several acyl glucuronides has been demon-
strated, including relevant drug examples, in an efficient two-step
synthesis (see [19] for phenylacetic acid examples). In addition, the
field is not static, and new chemical, biochemical, and biosynthetic
approaches continue to be developed, as outlined next.
Progress in synthetic methods for acyl glucuronides
The use of fully protected carbohydrate intermediates for acyl
glucuronide synthesis was revived by Nagao et al. [20]. Thus,
conversion of known allyl glucuronate 1 [21] to the tetra-allylox-
ycarbonyl derivative 2, followed by anomeric carbonate
hydrolysis, afforded hemi Q6acetal 3 (Fig. 1).
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i) RCO2H, see text
ii) Pd(PPh3)4
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IGURE 1
cyl glucuronide synthesis via a tetraallyl intermediate.
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Various carboxylic acids, following appropriate activation, were
coupled to 3 with excellent b:a selectivity, affording the desired
acyl glucuronide 4 after exhaustive Pd(0) deprotection (Fig. 2). The
authors recommend the chloropropenylamine derivative 5 as an
activator in this mode (Fig. 2). Gram quantities of the acyl glucu-
ronide of PPAR-g-agonist 6 were made in this way (Fig. 2).
The selective acylation method was recently refined by using a
chiral base catalyst [22]. Thus, acylation of carboxylic acids with
anomeric hemiacetal sugars, catalysed by a single enantiomer of
chiral base 7, afforded the corresponding glycosyl esters as a- or
b-anomers.Using(S)-7, theb-productwasexclusivelyformed;using
(R)-7, the a-anomer was preferred, with lower selectivity (Fig. 2).
Notably, (S)-ibuprofen could be esterified without epimerisation







Structures 5–13.(Fig. 2), but other pyranose sugars could be used; the concept has
not yet been tested for acyl glucuronidation.
Recent applications of existing synthetic methods
Enzyme-based methods and cell preparations
The chemoenzymatic approach of Baba et al. [23] is still used. Thus,
alkylation of carboxylic acid 9 with the appropriate anomeric bro-
mosugar afforded intermediate 10 exclusively as the 1b-anomer
(Fig. 2). After some optimisation, sequential enzymatic hydrolysis
of the acetates, then the methyl ester, afforded the desired acyl
glucuronide of 9 (Fig. 2); additionally, the authors determined the
degradation kinetics of both (2R)-and (2S)-isomers of the product.
Biotransformation continues to be used for direct glucuronida-
tion of drug molecules, including acyl glucuronides. Recently a8
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IEWtreptomyces strain SANK 60895 [24] was used for the syntheses of
he acyl glucuronides of the lipolysis inhibitor 11 and mycophe-
olic acid 12 (Fig. 2), although, in both cases, preparative high-
erformance liquid chromatography (HPLC) was needed to
eparate the acyl glucuronides from the simultaneously produced
ryl glucuronides. Finally, human microsomal preparations are
till used, as in the series of indole 3-carboxylic acid derivatives 13
ig. 2), three of which were converted to their acyl glucuronides in
his way [25].
elective acylation
everal examples of the use of the selective acylation method,
sing either allyl or benzyl glucuronate, have appeared; carboxylic
cids 14–21 converted to their acyl glucuronides in this way are
ummarised in Figure 3.
In Figure 3, 14 is itself an oxidative metabolite of amine 14a, a
ontrolled psychoactive [26]. Fasiglifam 15 is an agonist of the free
tty acid receptor (FFAR1, also known as GPR40); both 15 and a
ignificant metabolite 16 were converted to their acyl glucuro-
ides [27]. In a related medicinal chemistry programme [28], 17
as identified as a candidate versus GPR40 and was also exten-
ively metabolised as its acyl glucuronide.
The series of four acyl glucuronides derived from phenylpro-
ionic acid derivatives 18, related to ibuprofen (R1, R2 = H or
e; both R- and S-enantiomers of the monomethyl derivative),
ogether with acids 19 and 20, was prepared specifically for a
roteomic study with purified HSA (see further discussion later)
9]. Extending this concept further, the known acyl glucuro-
ide of diclofenac 21 was prepared [6] for a study of
lbumin adducts found in patients taking diclofenac (see





arboxylic acids converted to their acyl glucuronides by the selective acylation
 www.drugdiscoverytoday.comAssessment of the reactivity of acyl glucuronides
Transacylation of acyl glucuronides in buffer and plasma
The ester bond of the 1b-anomer is liable to nucleophilic attack
through two mechanisms: hydrolysis by hydroxide ions resulting in
the parent aglycone anda/b-glucuronicacid,and attack byadjacent
hydroxyl groups on the glucopyranose ring, which results in intra-
molecular transacylation. As is now well appreciated, the percentage
ofeach reactiondiffersaccording to thestructureoftheaglyconeand
the matrix in which the metabolite is present [30–32]. Within the
buffer, the transacylation reaction dominates, and hydrolysis to the
free aglycone at physiological pH can be relatively minor (although
the balance between the two outcomes changes rapidly in more
alkaline solutions). However, in plasma, hydrolysis of the acyl
glucuronide metabolite is the major reaction [33,34]. The transacy-
lation rate of the original acyl glucuronide and its various transa-
cylated forms in plasma also proceeds at different rates, as shown
by studies on the reactivity of diflunisal acyl glucuronide (DFAG)
isomers [35]. When the individual 1-, 2-, 3-, and 4-O-acyl positional
isomers were incubated (at 55 mg DF equivalents/mL) with HSA
(40 mg/mL, pH 7.4, 37 C) initial half-lives of 53, 75, 61, and 26 min
were measured, respectively. Whereas the 1-O-acyl isomer was sub-
ject to hydrolysis, the 2-, 3-, and 4-O-acyl isomers, especially the
latter, were more prolificat formingcovalent adducts of HSA adducts
compared with the 1-O-acyl form. Thus at 2 h, the 1-, 2-, 3-, and 4-O-
acyl positional isomers had formed adducts with HSA accounting for
2.4, 8.2, 13.7, and 36.6% of the amount originally present in the
incubation, respectively [35].
However, studies in aqueous buffer are technically simpler to
perform and are more widely used than plasma to assess the
potential reactivity of acyl glucuronides. In buffer, at pH 7.4,
after the initial transacylation to the 2b-anomer, subsequent15
17
21 20
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transacylation and anomerisation reactions result in the appear-
ance of multiple a/b-anomers until an equilibrium mixture is
attained. Measuring the disappearance of the 1b-anomer over
time because of transacylation and hydrolysis reactions in vitro
has been utilised as a measure of the overall reactivity of the acyl
glucuronide and has been termed the degradation rate (kd). Two
analytical techniques have been predominantly used for deter-
mining the kd: proton nuclear magnetic resonance (
1H NMR)
spectroscopy and HPLC with ultraviolet (UV) or mass spectro-
metric (MS) detection. Differences in rates of degradation deter-
mined by each technique have been observed; for example, the kd
for benzoic acid differed by approximately ninefold, being
0.039 h1 by 1H NMR spectroscopy [36] and 0.35 h1 by HPLC-
UV [37] Deuterated solvents have previously been shown to
decrease the rate of degradation of acyl glucuronides [38], which
might account for the differences observed between rate con-
stants determined by 1H NMR spectroscopy and HPLC-UV/MS.
This might be because of deuterium exchanging with the hydrox-
yl hydrogen of the glucopyranose ring, resulting in a decreased
rate of transacylation. However, the ability to perform such
studies in largely protonated solvents, including water, should
limit these differences in degradation rate determination by 1H
NMR spectroscopy [33,34].
The aglycone structure has been shown to affect the kd value
through both electronic and steric factors. In general, the inclu-
sion of electron-withdrawing groups (EWG) on the aromatic ring
adjacent to the ester bond enhances the rate of degradation, and
the inverse is observed for substitution with electron-donating
groups (EDG). This was clearly observed with the difference in
degradation rate of a series of para-substituted benzoic acids in-
vestigated by Vanderhoeven et al. [36,39]. 4-Nitrobenzoic acid had
a kd of 0.71 h
1, whereas replacing the electron withdrawing nitro-
group with EDGs, such as 4-methoxy- or 4-propoxy-substiuents,
decreased the rate of reaction to 0.013 h–1 and 0.007 h–1,
respectively, determined by 1H NMR spectroscopy.
Differences in the rate of degradation were also observed be-
cause of the position of the group around the benzoic acid ring,
measured by HPLC-UV. Baba and Yoshioka [37] investigated the
degradation of the acyl glucuronides of the ortho-, meta-, and para-
derivatives of chlorobenzoic acid, methylbenzoic acid, and phe-
nylbenzoic acid, along with the ortho- and para- derivatives of
methoxybenzoic and trifluoromethylbenzoic acid. The degrada-
tion of the meta- derivatives 3-chlorobenzoic acid, 3-methylben-
zoic acid, and 3-phenylbenzoic acid proceeded faster than their
equivalent para- metabolites for each series of compounds. The
ortho- species 2-methylbenzoic acid and 2-phenylbenzoic acid
were the slowest of their respective series, highlighting the role
of steric factors in the rate of degradation. 2-Chlorobenzoic acid
degraded slightly faster than the para- derivative, with a kd of
1.21 h1 compared with 0.61 h–1 for 4-chlorobenzoic acid. Simi-
larly, 2-methoxybenzoic acid was determined to have a kd of
0.146 h–1, which is faster than the para- derivative with a rate of
0.082 h–1. By contrast, 2-trifluoromethylbenzoic acid degraded
more slowly than the para- derivative, with a kd of 0.234 h
–1
compared with 1.79 h–1 for 4-trifluoromethylbenzoic acid [40].
These examples demonstrate that a mixture of electronic
and steric factors governs the rate of degradation of the acyl
glucuronide metabolites.Please cite this article in press as: Bradshaw, P.R. et al.The influence of steric hindrance has also been investigated
using a series of phenylacetic acid 22 (R1, R2 = H or Me; (R)- and (S)-
diastereoisomers of the monomethyl derivative; Fig. 4) and ibu-
profen 18 analogues (Fig. 3) [19,33]. Substitution of methyl groups
to the a carbon increased the stability of the acyl glucuronide
conjugate with the dimethyl derivatives of both series,
a,a0-dimethyl phenylacetic acid and 2-(4-isobutylphenyl)-2-
methylpropanoic acid (bibuprofen) having the slowest reaction
times, kd 0.029 h
1 and 0.025 h1, respectively, determined by 1H
NMR spectroscopy. In contrast the unsubstituted derivatives, phe-
nylacetic acid and ibufenac had more rapid reaction rates,
2.353 h1 and 0.516 h–1, respectively. In the case of the single
methyl substitution to give the (R)-diastereoisomers, (R)-a-methyl
phenylacetic acid and (R)-ibuprofen (kd 0.903 h
–1 and 0.472 h–1,
respectively) degradation was faster than the corresponding (S)-
diastereoisomers, (S)-a-methyl phenylacetic acid and (S)-ibupro-
fen (kd 0.405 h
–1 and 0.184 h–1, respectively). This pattern in
degradation between diastereoisomers has been observed with
multiple aryl propionic acid acyl glucuronide metabolites, includ-
ing benoxaprofen [41] carprofen [42], fenoprofen [43], ketoprofen
[44], and naproxen [45,46]. The (S)-diastereoisomers degrade at
approximately half the rate of the (R)-diastereoisomers (leading to
the easily remembered phrase ‘R for rapid, S for slow’). Here, we
have discussed the two major classes of aglycone documented in
the literature (benzoic acid and aryl acetic acid derivatives); the
reader is directed to [47] for further discussion of acyl glucuronides
reactivity on a diverse range of aglycone structures.
Target sites for covalent binding of acyl glucuronides on
albumin
Although transacylation/hydrolysis rates are useful indicators of
reactivity, clearly the ‘proof of the pudding’ of reactivity with
biomolecules, such as proteins, relies on direct evidence. Whereas
phenolic glucuronides, for example, are unreactive glycosidic
bonds, acyl glucuronides can react with proteins through both
transacylation and intramolecular acyl migration to form glyca-
tion and glycosylation products (Fig. 5). Advances in proteomic
techniques enable the detection of both protein adducts and their
sites and nature. Although relatively few detailed studies have
been performed, data from both in vitro and ex vivo studies have
been obtained and illustrate what can be achieved.
There is good, longstanding, evidence for the covalent binding
of acyl glucuronides to proteins in vivo and these modified proteins
then eliciting an immune response. An example is valproic acid,















































Nu = nucleophilic group
e.g O, NH, S
m/z = PROTEIN + DRUG
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FIGURE 5
The formation, reactions and putative products of nucleophilic groups on drugs. (a) Glucuronidation of nucleophilic groups (Nu) in drugs during conjugative
metabolism. A production of stable glucuronide glycosidic bonds (e.g., with phenolic groups). (b) Glucuronidation to produce acyl glucuronides, which can then












IEWrotein adducts of valproic acid were detected in plasma obtained
om both in vitro incubations and from patients with epilepsy
reated with the drug [48]. By using ELISA (developed with the aid
f HSA–drug adducts formed following incubation with a mixture
f the transacylated glucuronides anomers), the immunoreactivity
f plasma from 57 patients was tested. Of these, nine patients were
und to have low, but measurable, amounts of antibodies to HSA
odified in this way. However, the low titres were taken to
dicated that the drug–protein adducts had, in line with low
linical valproate hypersensitivity, similarly low immunogenicity.
owever, this early study nicely illustrates the progression from in
itro studies, which reveal the potential for HSA modification, to ex
ivo studies to better determine the biological response (or lack of
) in the patient. Several studies were able to pinpoint the sites of
ovalent adduction on HSA, such as those describing the binding
f tolmetin and benoxaprofen acyl glucuronides [49,50]. In the
ase of tolmetin [49], the adducts produced when its acyl glucuro-
ide was incubated in vitro with HSA were identified as either being
nked via the glucuronic acid primarily to Lys-199 and, in smaller
mounts, to Lys-195 and -525 or direct linkage of tolmetin itself to
sine (Lys-199 and 541), serine (Ser-220, 232, and 480) and Arg-
22 residues. In addition, there was indirect evidence for binding
f tolmetin acyl glucuronide to Lys-541, and binding of tolmetin
o Arg-521. These results established that binding of acyl glucur-
nides to various nucleophilic sites on proteins occurred mainly
ia imine formation, retaining the glucuronic acid, or alternatively
ia nucleophilic displacement of the glucuronic acid moiety. The
ame group used similar methods to study the covalent adducts
rmed when the acyl glucuronide of benoxaprofen was incubatedPlease cite this article in press as: Bradshaw, P.R. et al.
 www.drugdiscoverytoday.comwith HSA [50]. They found that benoxaprofen glucuronide was
formed by the condensation of transacylated acyl glucuronide
isomers of glucuronic acid and also displacement of glucuronic
acid. Unlike tolmetin, Lys-159 was found to be the major site of
these benoxaprofen-derived adducts, indicating that there were
compound-specific differences in the adduct-binding profiles.
Continuing advances in proteomic technologies have revealed
more details concerning the nature and extent of protein modifi-
cation. Recent studies showed the effect of the structure of the acyl
glucuronide upon adduct formation following in vitro incubation
of a range of acyl glucuronides [ibufenac, (R)-/(S)-ibuprofen,
bibuprofen, p-bromobenzoic acid and ponalrestat] with HSA at
concentrations typical of those encountered in therapy [29]. This
study showed that, for most of the compounds tested, adduct
formation via both transacylation and glycosylation could occur
(although glycosylation predominated for p-bromobenzoic acid
acyl glucuronide), with small amounts of dual adducts formed for
ibufenac and (R)- and (S)-ibuprofen (Fig. 6). The resulting protein
product ratios that were obtained related to the degree of a-sub-
stitution to the acyl group, and a lack of a-substitution correlated
with higher reactivity as determined by HSA adduction. As
discussed earlier, in vitro degradation in buffer of the phenylacetic
acid [19] and ibuprofen series [33] is related to a-substitution and
there might be a correlation between in vitro kd and the type of
protein adducts formed. Of particular interest is that the pattern of
protein modification by the acyl glucuronides varied greatly with
structure. However, as seen with the earlier studies, Lys-137, 195,
199, 436, and 525 were modified, with Lys-137 and 436 showing
glycosylation and transacylation-derived adducts.
Drug Discovery Today Volume 00, Number 00  July 2020 REVIEWS
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FIGURE 6
The sites and reactivity of acyl glucuronide metabolites with human serum albumin (HSA). The sequence map shows the primary amino acid sequence with
disulfide bonds shown in yellow. Reaction sites are shown for in red for glycosylation, transacylation sites are indicated in blue, whereas Lys-525, which had both














Studies undertaken on the reaction of synthetic diclofenac acyl
glucuronide, and then patient-derived HSA revealed a similarly
interesting and complex pattern of adduction [6]. In vitro incuba-
tions of the diclofenac metabolite with HSA at a molar ration ofPlease cite this article in press as: Bradshaw, P.R. et al.50:1 showed both glycation and transacylation at Lys-137, 190,
195, 199, 351, 432, 436, 525, and 451 with, in addition, glycation
at Lys-162. However, at lower glucuronide:HSA ratios (e.g., 0.1:1),





































































IEWom six patients was analysed with the same methodology,
odification of seven lysine residues was observed, with seven
-acylations and three acyl glucuronide glycations. The transacy-
tion to Lys-195 was seen for all the patients, whereas one patient
ad seven lysine adducts. The in vitro studies were not entirely
ccurate predictors of the in vivo result, with adducts of Lys-137
nd 351 not detected. However, as the authors noted for these
atients, none of whom showed evidence of diclofenac-related
ypersensitivity, ‘albumin adduction is not inevitably a causation
f hypersensitivity to carboxylate drugs or a coincidental
ssociation’ [6].
uantitative structure–property relationship models
ultiple quantitative structure–property relationship (QSPR)
odels have been developed to identify and quantify the struc-
ural features of the aglycone, which might be useful for pre-
icting the rate of degradation. Given the nucleophilic nature of
he transacylation and hydrolysis reactions, the electron densi-
y at the carbonyl carbon is likely to be key for predicting kd
alues. Vanderhoeven et al. [36,39] investigated electronic
ffects on the rate of degradation of acyl glucuronide metabo-
tes with a series of para-substitution benzoic acid acyl glucur-
nides, as discussed earlier. Hammett constants showed good
orrelation (R2 = 0.95, N = 10), with the logarithm of the degra-
ation rate constant (log kd). Baba and Yoshioka [37] identified a
imilar correlation with a series of meta- and para-substituted
enzoic acid (R2 = 0.98, N = 10). Partial atomic charges of the
arbonyl carbon of the ester bond calculated using different
opulation analysis schemes were investigated as descriptors for
redicting log kd. Calculations at the Hartree–Fock level with
he STO-3 G basis set using Mulliken population analysis
esulted in the closest correlation (R2 = 0.96, N = 10) with log
d of the population analysis schemes investigated [39]. Similar
esults were observed by Yoshioka and Baba [40] at the B3LYP/6-
1G* level of theory with water simulated as the solvent using
atural population analysis for the charge on the hydrogen
R2 = 0.94, N = 10) and oxygen atoms (R2 = 0.95, N = 10).
Vanderhoeven et al. [39] also investigated the correlation be-
ween measured 13C NMR shifts of the carbonyl carbon and the
egradation rate. The chemical shift for the parent benzoic acid
2 = 0.78, N = 9), ethyl ester (R2 = 0.78, N = 9) and acyl glucuronide
2 = 0.79, N = 9) showed similar correlation with the log kd. Simi-
r results were observed by Baba and Yoshioka [37] with the
rtho-, meta- and para- benzoic acid aglycone series (R2 = 0.84,
 = 16) and their corresponding acyl glucuronide (R2 = 0.88,
 = 16). These authors also performed further linear regression
ith their meta- and para-substituted benzoic acids and identified
he experimental measured pKa (R
2 = 0.94, N = 10) and calculated
Ka (R
2 = 0.97, N = 10) as useful descriptors for predicting log kd
0]. In addition to single linear regression, multiple linear regres-
ion models combining electronic (NMR chemical shifts, partial
tomic charge, and calculated pKa) and steric descriptors (NMR
hemical shifts and Taft E parameters) were developed (R2 = 0.90–
.92, Q2 = 0.78–0.89, N = 18) for the series of 18 ortho-, meta and
ara-substituted benzoic acids (see Table 6 in [40]). Similar regres-
ion models were developed using electronic and steric descriptors
r a separate series of aralkyl carboxylic acids [51]. Potter et al. [52]
lso developed a partial least squares regression model using 13CPlease cite this article in press as: Bradshaw, P.R. et al.
 www.drugdiscoverytoday.comNMR chemical shifts and Sterimol steric parameters of methyl
esters as a proxy for acyl glucuronide activity.
The models discussed earlier focused on the calculation of
simple descriptors of the parent aglycone, ethyl ester, or conjugate
to predict the rate of degradation. Berry et al. [19] used a more
sophisticated approach by modelling the initial transacylation
reaction using density functional theory (DFT). They identified
the transition structures for four phenylacetic acid 22 acyl glucu-
ronide derivatives and calculated the activation energy between
the ground state and transition structure using B3LYP/6-31++G(d,
p)//B3LYP/6-31 G(d,p) model chemistry. The calculated activation
energy showed good correlation with kd (R
2 = 0.98, N = 4), as did
the energy of the lowest unoccupied molecular orbital (ELUMO)
(R2 = 0.90, N = 4). The activation energy of the transacylation
reaction accounts for both electronic and steric elements that
affect the rate of degradation and has potential to be a useful
descriptor for accurate prediction of degradation. However, be-
cause of the larger size of the molecular system (acyl glucuronide
conjugate) compared with simply optimising the aglycone struc-
ture and the need to identify the transition structures, this method
is more time and computationally intensive than methods dis-
cussed earlier. Currently, this methodology has examined a limit-
ed subset of acyl glucuronides and its application is currently being
extended by examining more acyl glucuronide and acyl glucoside
structures. Acyl glucosides are a related set of metabolites that
undergo transacylation and hydrolysis reaction analogous to their
glucuronide counterparts [53,54]. The above methodology was
recently successfully applied to the equivalent acyl glucoside series
[54] of phenylacetic acid studied by Berry et al. [19].
For QSPR model development in general, the larger the data set
the better; the models discussed earlier were built on small conge-
neric series, which limits their application. Recently, Tugcu and
Sipahi [55] developed a global model using a large diverse training
set of aglycone structures. Their data set contained 67 acyl glucur-
onides (collated in [47]), and 3100 descriptors were calculated for
each aglycone structure using multiple cheminformatic software.
Feature selection was performed with the genetic algorithm meth-
od before the development of linear regression models. From the
feature selection, the four-descriptor regression model reported
had the number of quaternary carbons (nCq), ring complexity
index (RCI), burden eigenvalues (BELe6), and edge adjacency
indices (ESpm07d) as key features (R2 = 0.69, Q2 = 0.57, N = 67).
As expected, the model had a combination of descriptors that
capture steric and electronic effects.
However, the data set used for the model comprised half-life
values for the compounds determined by either NMR spectroscopy
or HPLC-MS; for example, values for the phenylacetic acid 22
series [phenylacetic acid, (R)-/(S)-2-phenylpropionic acid and 2-
methyl-2-phenylpropionic acid] were determined by NMR spec-
troscopy [19,47,55], whereas half-lives for fenclofenac, levoflox-
acin, meclofenamic acid, and repaglinide were determined by
HPLC-MS/MS [8,47,55] [as a note, it appears there is an incorrect
value for the phenylacetic acid half-life (1.05 h), whereas 0.29 h
was reported in the original article [19]]. As discussed earlier, the
degradation rate determined for a compound can differ greatly
depending on the analytical technique used, especially if NMR
spectroscopy was performed in D2O. Another potential limitation
of this model is that half-live values for diastereoisomers were
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averaged for the aglycone and entered as a single data point
[e.g., (R)-/(S)-2-phenylpropionic acid, (R)-/(S)-ibuprofen, (R)-/(S)-
ketoprofen, etc.]. As discussed earlier, the diastereoisomers follow
the general pattern of the (R)-diastereoisomers degrading approxi-
mately twice as fast as the (S)-diastereoisomers. The aryl propionic
acid class of molecules has been studied extensively in drug
development (include many NSAIDs) and, therefore, for accurate
prediction of kd and half-lives, it would be more appropriate to
distinguish between the diastereoisomers as separate data points.
This distinction is often difficult using molecular descriptors based
on the aglycone structure because the values are often the same or
similar for the (R)- and (S)-diastereoisomers. Despite the disadvan-
tage of the added time and computation, the methodology
presented by Berry et al. [19] and Bradshaw et al. [54] has the
advantage that it can distinguish between the diastereoisomers
because of differences in the geometry (and, therefore, energy) of
the (R)- and (S)-conjugates. In addition, the authors examined the
correlation of descriptors individually with subclasses of acyl
glucuronide (R = 0.78–>0.99; see Table 4 in [55]). Examination
of individual classes of aglycone decreased the sample size (N = 5–
30) compared with the global model, which was a limiting factor
for the models discussed earlier developed by other authors
[19,36,37,39,409,51,52].
Based on the current published in vitro data, there is a trade-off
between developing a model on a large data set (which, therefore,
includes multiple classes of aglycone) resulting in lower accuracy,
or alternatively developing a specific model for a class of conju-
gates (e.g., benzoic acids or aryl acetic acids), limiting the applica-
tion of the model and potentially resulting in overfitting because
of the small training set. Augmentation of the in vitro kinetic data
available in the literature for acyl glucuronides with a larger range
of aglycone structures, with care taken to ensure the same analyti-
cal technique, was used to have a defined endpoint, would be
beneficial to the development of accurate predictive models.
Evaluating the risk posed by acyl glucuronides: model
systems for hypothesis testing
Although the potential hazard posed by acyl glucuronides is clear,
and an assessment of sorts can be made using simple measure, such
as transacylation rates in buffer, obtaining a predictive evaluation
of risk is more problematic. This is especially the case when there
are other, competing, routes for toxification, such as reactive
oxidative metabolism or S-acyl-CoA thioester formation [56].
However, a toolbox of in vitro, in vivo, in silico, and ex vivo studies
is available that, although by no means fully developed, enables a
more nuanced approach to predicting risk if used sensibly.
In vitro systems
Although perhaps of limited value, measuring the rate of transa-
cylation in buffer is simple to undertake, can be performed on
limited amounts of material (as might be obtained from in vitro or
animal studies), and can act as a flag for the need to perform
additional studies. We would suggest that the first of these would
be incubation with proteins, such as HSA, to assess the potential
for covalent binding. The sites and relative amounts of covalent
modification can then be assessed using proteomic techniques, as
outlined earlier. If reactivity against target proteins appears high,
then absolute amounts of covalent binding can be determined viaPlease cite this article in press as: Bradshaw, P.R. et al.the use of radiolabelled drug. However, as noted in the Introduc-
tion, metabolism of carboxylic acid-containing drugs to both acyl
glucuronides and reactive S-acyl-CoA thioesters occurs widely, and
both types of metabolite bind to protein. Indeed, the latter have
been shown to provide 40–70 times the level of covalent binding
to proteins compared with acyl glucuronides [12] A plausible
hypothesis is then that acyl glucuronidation is acting as ‘a canary
in the mine’, and is merely a surrogate marker for S-acyl-CoA
thioester biosynthesis/reactivity, and that the latter is the real
toxin. In addition, both types of reactive conjugate might be
irrelevant if the real cause is oxidative bioactivation. However,
methodology for assessing the relative contributions of both
oxidative and conjugative biotransformations, and capable of
distinguishing between all three metabolic fates, has been devel-
oped using human liver microsomes [12]. Here, microsomal pre-
parations were supplemented with either NADPH (for oxidative
metabolite production), uridine 50-diphosphoglucuronic acid
(UDPGA) (for acyl glucuronide formation), or CoA (to allow
production of S-acyl-CoA thioesters). This system provides a read-
ily implemented means for the separate study of the biosynthesis
and reactivity of each type of metabolite. When applied to the
investigation of ibuprofen, tolmetin, ibufenac, fenclozic acid,
tienilic acid, suprofen, and zomepirac, all seven drugs formed acyl
glucuronides, but no covalent binding to protein was detected as a
result. By contrast, this methodology demonstrated that the CoA
conjugates of ibuprofen, ibufenac, fenclozic acid, and tolmetin
were highly reactive and, indeed, the highest levels of covalent
binding achieved were seen with ibuprofenyl-CoA and ibufenacyl-
CoA (1000 and 8600 pmol drug eq/mg protein, respectively) [12].
This observation is interesting because it is well known that
racemic (R)-/(S)-ibuprofen is subject to significant conversion of
the inactive (R)- form to the active (S)-ibuprofen and that the
formation of acyl-CoA thioesters is central to the chiral inversion
(which is also seen for many other racemic profens). via their acyl-
CoA thioesters, these profens can be further metabolised into
lipids, such as hybrid triglycerides, and accumulated in adipose
tissue and cell membranes [57]. In addition, they can affect lipid
metabolism in a variety of ways [56]. Therefore, the reason for the
lower covalent binding seen for ibuprofen versus ibufenac might
not necessarily be because of reduced formation but might reflect
the near tenfold difference in the reactivity of their acyl-CoA
thioesters. Given that ibufenac was rapidly withdrawn from clini-
cal use, whereas ibuprofen remains a popular, and relatively safe,
over-the-counter NSAID, it is tempting to speculate that, had these
relative covalent binding potency measurements been available at
the time, the latter would have been selected over ibufenac for
further development. In the same study, both suprofen and tienilic
acid showed much higher reactivity for their oxidative metabolites
(250 pmol drug eq/mg protein each) than was attributable to
either acyl glucuronides or CoA conjugates.
More recently Shang et al. [11] used a similar approach to
investigate the reactivity of a drug candidate, MK-8666 (trometha-
mine) designed to be a selective GPR40 agonist for use in type 2
diabetes mellitus, but the development of which was terminated as
a result of apparent DILI. Covalent binding studies were undertak-
en using liver microsomes, as well as rat and human hepatocytes,
to determine the role, if any, of reactive metabolites in the ob-




































































IEWn acyl glucuronide in human hepatocytes and both acyl glucu-
onide and taurine conjugates in those of rat. Irrespective of
pecies, the amounts of protein binding were similar. Proteolysis
nabled the identification of a range of transacylated products to
sine, serine, and cysteine, as well as glycation adducts. The latter
as produced via the rearrangement of the 1-O-b-acyl form of the
lucuronide to ring-opened aldehydes capable of condensing with
sine in the proteins as imine adducts. Notably, increased
mounts of protein binding were detected when the microsomes
ere supplemented with either CoA or ATP compared with that
een with microsomal incubations fortified with UDPGA. When
lutathione was added to the MK-8666 incubation, the amount of
inding attributable to CoA thioester formation was reduced by
40%. Therefore, this study provides another demonstration of
he ability of this methodology to separate and quantify the
arious sources of covalent protein modification produced as
he result of exposure to acidic drugs (or their metabolites).
Obviously, more advanced cellular models, such as hepatocytes,
lso have potential for providing this type of information, includ-
g systems using inhibitors of CYP450, or the HepG2 cell line,
here P450 activity is low. In the case of glucuronidation, the
atural product (-)-borneol can provide some inhibition of acyl
lucuronide formation, but this is not always complete. For exam-
le, in the case of the acyl glucuronide of valproic acid, hepato-
ytes incubated with 1 mM (-)-borneol clearly reduced production
f the conjugate (but did not eliminate it) without any effect on
he chosen markers of toxicity [58]. In the case of diclofenac acyl
lucuronide production (used as a positive control in the study),
o effect was detected on the production of its acyl glucuronide.
y contrast, hepatocyte investigations on the drug fasiglifam
AK-875) using a radiolabelled form of the drug attributed the
ignificant covalent binding observed to a reactive acyl glucuro-
ide and/or an acyl-CoA thioester [59] This conclusion was made
n the basis that co-incubation of hepatocytes with CYP450
hibitor 1-aminobenzotriazole (ABT) had little effect on covalent
inding, whereas (-)-borneol reduced it significantly (40%). Diclo-
nac, used as a positive control, had its covalent binding reduced
y both ABT and borneol. Although hepatocytes are clearly useful,
 would appear that the easiest screen to introduce initially would
e one based on hepatic microsomes, which offer the potential to
vestigate each of these potential metabolic fates separately.
epatocytes might then be used for subsequent studies.
 vivo systems
he availability of efficient methods for the synthesis of gram
uantities of acyl glucuronides removes one practical barrier to
heir in vivo testing, but several others remain, a major one being
tability. If orally administered acyl glucuronides are unlikely to be
bsorbed to any extent, they will probably not survive because of
hemical stability issues and the effects of bacterial glucuronidase
lthough this can be ameliorated). This means that not only will
he test compounds have to be administered intravenously, but
hey may also require long infusions to maintain any level of
xposure. Uptake into target organs, such as the liver, might also
e limited and, taken together, these factors do not make this a
articularly attractive approach.
However, where the metabolic fate of a drug, or drug candidate,
 solely through acyl glucuronide formation, the extent ofPlease cite this article in press as: Bradshaw, P.R. et al.
0 www.drugdiscoverytoday.comexposure and adverse effects, together with the amount of cova-
lent binding, is relatively easy to determine (although interpreta-
tion might still be problematic) using conventional studies. Where
glucuronidation is the major route of metabolism models, such as
that established in the mouse, investigating the renal toxicity of
zomepirac [60] can be useful. This study involved the use of both
the esterase inhibitor tri-O-tolyl phosphate (esterases, in addition
to glucuronidases, hydrolyse acyl glucuronides [61]) and the glu-
tathione biosynthesis inhibitor BSO to explore the mechanism of
tissue damage. In cases where there is a mixture of oxidative
metabolism to reactive metabolites, acyl-CoA thioester and acyl
glucuronide formation in vivo evaluation is obviously more prob-
lematic, and more difficult to dissect than in vitro systems. A partial
solution can be found in the use of, for example, mice in a study of
diclofenac-induced DILI, where (-)-borneol was used to inhibit
glucuronidation [62] and both a reduction in DAG concentrations
and markers of hepatic injury were seen compared with controls.
Alternatively, genetically modified mice can be used, such as the
hepatic reductase null (HRNTM) mouse, where hepatic CYP 450s
are essentially inactive, eliminating reactive metabolite formation
by this route. However, conjugative metabolism still occurs in the
livers of HRNTM mice and both glucuronide and amino acid
conjugates are formed. The latter is important because the amino
acid conjugates (most often to glycine in human and taurine in
mouse), produced in the mitochondria, require the biosynthesis of
an acyl-CoA thioester [63] However, such thioester formation does
not always result in amino acid conjugation [e.g., acyl-CoA thioe-
sters of (R)-ibuprofen appear to be recycled predominantly as (S)-
ibuprofen, not the glycine conjugate in humans]. When compared
with normal C57Bl6 mice, which produce a mixture of oxidative
metabolites and (mainly) taurine, ether, and (small amounts of)
acyl glucuronide conjugates, HRNTM mice form essentially only
the acyl glucuronide and taurine conjugates. Thus, by comparing
metabolic profiles in both conventional and HRNTM mice, it is
possible to demonstrate that metabolism is either largely confined
to the liver, or also subject to extrahepatic metabolism (e.g.,
[64–66]). If, for example, in studies in normal and HRNTM mice,
the bulk of metabolism can be assigned to the liver, then a better
idea of the overall metabolic fate could be obtained using chimeric
liver humanized mice. In these animals, most mouse hepatocytes
are replaced with metabolically competent human-derived cells.
With drugs such as fenclozic acid [67] or diclofenac [68], where
metabolism is largely via the liver, humanized mice showed that
large amounts of the acyl glucuronide conjugate (accompanied by
smaller quantities of the transacylated glucuronides) were
produced, with taurine conjugates representing only a minor
component [67,68]. By contrast, taurine conjugates represented
a larger proportion of the total metabolite profile in normal mice,
suggesting that these humanized mice give a better reflection of
the likely exposure of humans to acyl glucuronide [67,68].
Ex vivo studies in humans
Clearly, as described earlier, there is unequivocal evidence for
covalent binding to, for example, HSA in the circulation of
patients receiving drugs, such as diclofenac [6] and valproic acid
[48]. Equally clearly, the presence of these circulating acyl glucu-
ronide-modified proteins does not automatically indicate the
likelihood for a subsequent ADR. However, using proteomic
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techniques, it should be feasible to assess this covalent binding for
a range of acyl glucuronide-forming drugs in both animals and
humans. From this, it might be possible to determine whether
there is a predictive QSAR that can distinguish between toxic
compounds, perhaps based on the sites and types of modification,
and those that are not, which could be used in risk assessment. It
should also be possible to obtain a measure of the immunogenicity
of these modified proteins.
Concluding remarks and perspective
Despite many years of speculation and investigation, there is still
no clear and unambiguous evidence that acyl glucuronides are
toxic as a result of reactivity. Certainly, many compounds that do
form these conjugates have been associated with DILI, and a
significant subset of these have been withdrawn. However, as
has often been pointed out, many DILI-causing compounds
(e.g., diclofenac), which form acyl glucuronides with short in vitro
half-lives, are also subject to oxidative metabolism and S-acyl Co-A
conjugate formation, and both also produce reactive metabolites.
However, although it can be argued that the presence of the
carboxylic acid group is key, and whether it is the acyl glucuronide
or S-acyl CoA-metabolite that is the source of the covalent binding
is a detail, it is difficult to disentangle these from the reactive
oxidative metabolites. However, synthetic methods are now avail-
able that can produce high-purity acyl glucuronides in hundreds
of milligram to gram quantities if required to enable further
testing, if only the appropriate tests can be devised. A variety ofPlease cite this article in press as: Bradshaw, P.R. et al.in vitro, in vivo, and ex vivo models are also available that could
provide insight into likely risk.
With advances in computational power, molecular systems can
be modelled in greater detail. As discussed earlier, DFT has been
utilised to model the intramolecular transacylation transition
structures of a limited number of acyl glucuronide metabolites.
Further investigations into a larger series of acyl glucuronides will
be useful for determining whether this methodology is effective
for QSPR development. In addition, modelling of large systems,
including proteins, has become a growing field in recent decades.
Calculations using hybrid quantum mechanics/molecular me-
chanics (QM/MM) have been applied to study the active site of
enzymes and ligand interactions with proteins and DNA (see Table
2 in [69] for a list of studies applying QM/MM to biomolecules).
This technique could be used to study the mechanism of protein
adduct formation of acyl glucuronides and S-acyl-CoA thioesters,
potentially aiding the identification of the mechanism(s) of tox-
icity. The key point that needs resolution at the moment, as
highlighted by Boelsterli in 2002 [56], is probably that ‘more work
is needed to provide a causal link between protein-reactive
acyl glucuronides and acyl-CoA thioesters and the rare and
unpredictable idiosyncratic drug reactions in humans’, or indeed
to demonstrate whether there is a genuine link between either (or
both) of these reactive metabolites and toxicity. Q
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